louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02141685: Correlating Time-Lapse Parameters With aCGH Testing in IVF Treatment (aCGH Study)
Official title: Correlating Time-Lapse Parameters Detected by Eeva™ With Array-Comparative Genomic Hybridization Results and Ongoing Pregnancy Rates (aCGH Study)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Infertility
Keywords: in vitro fertilization
assisted reproduction techniques
noninvasive imaging of embryos
time lapse imaging of embryos
traditional morphological grading of embryos
prediction of blastocysts
infertility
preimplantation genetic diagnosis
array-Comparative Genomic Hybridization
Lead sponsor: Progyny, Inc.
Sponsor class: INDUSTRY
First posted: 2014-05-19
Enrollment: 50
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 43
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women undergoing fresh IVF treatment and undergoing aCGH testing, as recommended based on medical need by the clinical site reproductive endocrinologist.

Brief summary: The purpose of this research study protocol is to collect imaging data on embryos followed to blastocyst stage (Day 5-6) and correlate Eeva parameters with array - Comparative Genomic Hybridization (aCGH) results and ongoing pregnancy rates.

Detailed description: The present study was designed to determine if there is a correlation between the Eeva System parameters and aCGH testing results. Embryos will be selected for transfer based on aCGH results and morphology. The Clinical site will have no access to the Eeva analysis at the time of the transfer.

Eligibility criteria: Inclusion Criteria:

* Subject is ≤43 years of age.
* Women undergoing IVF treatment with planned aCGH testing using her own eggs or donor eggs.
* Antral Follicle Count ≥ 6 at time of cycle start
* Baseline (day 2-3 of cycling) FSH ≤ 15 mIU/ml
* Antimüllerian Hormone level ≥ 0.5 ng/mL
* Fertilization using only ejaculated sperm (fresh or frozen) - no surgically retrieved sperm.
* Willing to have all 2PN embryos monitored by Eeva
* Not previously enrolled in this study.
* Willing to comply with study protocol and procedures and able to speak English.
* Willing to provide written informed consent.

Exclusion Criteria:

* BMI ≥ 40
* Prior IVF cycle with \< 4 x 2PN
* Planned Day 3 Assisted Hatching

Primary outcomes:
measure: Eeva time-lapse parameters and aCGH testing results
timeFrame: 5-6 days
Secondary outcomes:
measure: Embryo Implantation Rate
timeFrame: 6 weeks
measure: Clinical Pregnancy Rate
timeFrame: 6 weeks
measure: Ongoing pregnancy rate
timeFrame: 8-12 weeks
Other outcomes:
Locations:
city: Bryn Mawr
country: United States
facility: Main Line Fertility
state: Pennsylvania
Study officials:
affiliation: Progyny, Inc.
name: Shehua Shen, MD, ELD
role: STUDY_DIRECTOR
References:
Clinical trial NCT03856385: Impact of Mindful Walking Intervention on Daily Step Count
Official title: Impact of Mindful Walking Intervention on Daily Step Count: A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Physical Inactivity
Lead sponsor: Clemson University
Sponsor class: OTHER
First posted: 2019-02-27
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Mindful walking is a meditation practice that combines physical activity and mindfulness practice. This study examined whether a mindful walking intervention increased physical activity and improved health outcomes. The investigators conducted a randomized experiment among adults with inadequate physical activity, whereby the intervention group received a four-week, one-hour-per-week mindful walking intervention and the control group received instructions to increase physical activity (N=38). Participants in both groups received a wrist-worn step count device as participation incentive. Physical activity and health outcomes were measured with an online survey and data obtained from the wearable device at baseline (T1), post-intervention (T2), and one month after the intervention (T3).


Eligibility criteria: Inclusion Criteria:

* Adults over age 18
* Able to read and understand English

Exclusion Criteria:

* Student athletes
* Medical condition that limits slow-paced walking for 20 minutes

Primary outcomes:
measure: Rapid Assessment of Physical Activity Scale
timeFrame: one week
measure: Daily Step Counts
timeFrame: one day
measure: Screen Time
timeFrame: one week
Secondary outcomes:
measure: Perceived Stress Scale
timeFrame: one month
measure: Mental Health Inventory
timeFrame: one month
measure: Brief Edinburgh Depression Scale
timeFrame: 7 days
measure: Freiburg Mindfulness Inventory
timeFrame: 7 days
measure: Pittsburgh Sleep Quality Index
timeFrame: one month
Other outcomes:
Locations:
city: Clemson
country: United States
facility: Clemson University
state: South Carolina
Study officials:
affiliation: Clemson University
name: Lu Shi, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06133985: Effects of Costovertebral Joint Mobilization on Respiratory Function in Asthmatic Patients
Official title: Effects of Costovertebral Joint Mobilization on Respiratory Function in Asthmatic Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Asthmatic
Keywords: costovertebral joint mobilization
chest tightness
asthma
respiratory function
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2023-11-18
Enrollment: 28
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this randomized controlled trial is to determine the effectiveness of costovertebral joint mobilization on lung function in asthmatics. By targeting the thoracic region, costovertebral mobilization can play a valuable role in enhancing respiratory function and improving the overall well-being of individuals with respiratory conditions.

Detailed description: Costovertebral joint mobilization can help to improve this by increasing the mobility of the ribs and thoracic spine, which can help to expand the chest and improve lung function. Additionally, costovertebral joint mobilization can help to reduce muscle tension in the chest and upper back, which can also contribute to improved respiratory function. This is because tense or tight muscles can restrict the movement of the rib cage, limiting the ability of the lungs to expand and contract. Mobilization are performed in three positions, sitting, supine lying and side lying with arm abducted of the side to be mobilized. The improvement by regular physical training of breathing technique and chest wall mechanics may be explained by mobilization of the costovertebral articulations.

Eligibility criteria: Inclusion Criteria:

* Force Expiratory Volume 1/Force Vital Capacity ratio less than 0.7
* Mild asthma (Force Expiratory Volume 1 over 70% predicted)
* Chest tightness (inspiratory muscle tightness)
* Altered Dyspnea index.

Exclusion Criteria:

* presence of any underlying lung condition other than asthma.
* significant cardiovascular or musculoskeletal disease that may compromise the participant's capacity to participate in physical activity;
* active cancer.
* uncontrolled hypertension or diabetes.

Primary outcomes:
measure: Assessment of respiratory function FEV1 using spirometer.
timeFrame: 3 weeks
measure: Assessment of respiratory function FVC using spirometer.
timeFrame: 3 weeks
measure: Tape for chest expansion
timeFrame: 3 weeks
measure: Dyspnea index
timeFrame: 3 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Rahim Hospital
state: Punjab
Study officials:
affiliation: Riphah International University
name: Asghar Khan, DPT,DSc PT
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04025385: High-Intensity-Interval-Training in Geriatric Rehabilitation - A Feasibility Study
Official title: High-Intensity-Interval-Training in Geriatric Rehabilitation - A Feasibility Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Rehabilitation
Post-Operative Condition
Deconditioning After Acute Hospital
Oncology
Lead sponsor: Klinik Valens
Sponsor class: OTHER
First posted: 2019-07-18
Enrollment: 60
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Study with Patients (40-60 participants) above the age of 65. There will be a comparison of regular training on ergometer (10 trainings within 2 weeks, 40 min each) to high intensity interval training on ergometer (6 trainings within 2 weeks, 25 min each). At the beginning and at the end will be a spiroergometer to measure the individual limits and vO2max, which will be compared amongst the two groups. To receive a subjective feedback, there will be a series of questionnaires at the beginning, after one week and at the end. The goal of this study is to get more information about whether a HII-Training is feasible with elderly patients and whether they can profit form it.


Eligibility criteria: Inclusion Criteria:

* cardiopulmonal resilient
* able to sit on a ergometer
* knowledge of German written and spoken

Exclusion Criteria:

* Severe cardiopulmonary restriction (LVEF \<30%, conduction abnormalities from AV block IIb or higher)
* Absolute cardiopulmonary contraindications (acute coronary syndrome, unstable AP -\> not capable of rehabilitation), uncompensated heart failure (dyspnea at rest, orthopnea, severe edema)
* No ischemic events (cardiac, cerebral, peripheral) within the last 3 months
* Severe pneumatological underlying disease: COPD GOLD 3 and higher or status after exacerbation within the last 2 weeks, Asthma grade 4
* Dyalisis reliant
* Severe psychiatric disorder (severe psychosis, severe depression)
* Distinct dementia

Primary outcomes:
measure: Will there be a change in outcome of individuals vO2max?
timeFrame: 2 Weeks
measure: Is a High intensity interval training feasible with elderly patients in rehabilitation?
timeFrame: 1 Day
Secondary outcomes:
measure: Will there be a change in subjective quality of life?
timeFrame: 2.5 Weeks
Other outcomes:
Locations:
city: Walenstadtberg
country: Switzerland
facility: Rehazentrum Walenstadtberg
Study officials:
References:
Clinical trial NCT05343585: Validity of an AI-based Program to Identify Foods and Estimate Food Portion Size
Official title: Testing the Validity of an Artificial Intelligence-based Program to Identify Foods and Estimate Food Portion Size Among Adults, a Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nutrition Assessment
Keywords: Nutrition Assessment
Lead sponsor: Pennington Biomedical Research Center
Sponsor class: OTHER
Collaborators: name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2022-04-25
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 62
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The purpose of this study is to test the accuracy of the Nutrition Artificial Intelligence in the Openfit app during meals in a controlled laboratory setting

Detailed description: For this pilot study, using a convenience sample, the investigators will recruit up to 25 adults to use the Nutrition AI technology in Openfit to identify and estimate portion size of foods plated in a laboratory setting at Pennington Biomedical Research Center (PBRC) and/or Louisiana State University (LSU). Laboratory members within the Ingestive Behavioral Laboratory will also test the ability of Nutrition AI to identify foods and to quantify foods provided in the laboratory. Meals will be simulated, and participants will not consume the foods provided.

Eligibility criteria: Inclusion Criteria:

* Male or female
* Aged 18-62 years
* Self-reported body mass index (BMI) 18.5-50 kg/m2

Exclusion Criteria:

* Any condition or circumstance that could impede study completion
* Unfamiliar with or not able to use an iPhone

Primary outcomes:
measure: Identification of Food Plated Using the Openfit Mobile App
timeFrame: One study visit of ~2 hours
measure: Portion Size Estimation (kcal) of Food Plated Using the Openfit Mobile App
timeFrame: One study visit of ~2 hours
measure: User Satisfaction of the Openfit Mobile App for Recording Food Plated
timeFrame: One study visit of ~2 hours
measure: Usability of the Openfit Mobile App for Recording Food Plated
timeFrame: One study visit of ~2 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Baton Rouge
country: United States
facility: Pennington Biomedical Research Center
state: Louisiana
Study officials:
affiliation: Pennington Biomedical Research Center
name: Chloe P Lozano, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04468685: Ondansetron Effect on Pain Relief After Laparoscopic Cholecystectomy
Official title: Efficacy of Intraperitoneal Ondansetron Administration on Pain Relief After Laparoscopic Cholecystectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cholecystitis
Lead sponsor: National Hepatology & Tropical Medicine Research Institute
Sponsor class: OTHER_GOV
First posted: 2020-07-13
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Laparoscopic cholecystectomy (LC) is an easy procedure characterized by its minimal invasiveness, less post-operative pain and early recovery when compared to the open conventional cholecystectomy. However, patients who have undergone LC still complain of postoperative pain. It has been reported that ondansetron produces numbness when injected under the skin and has local anesthetic effect that is 15 times more potent than lidocaine the most widely used local anesthetic and probably explains its antiemetic action. It possesses anti-inflammatory, anesthetic, and analgesic properties by its multifaceted actions as a 5-HT3 receptor antagonist, a Na channel blocker, and a mu-opioid agonist which may have a potential role in decreasing pain. The study aimed to demonstrate the effectiveness of IP administration of ondansetron on pain management post LC.


Eligibility criteria: Inclusion Criteria:

* Patients who are scheduled to undergo elective LC

Exclusion Criteria:

* Patients undergoing chronic pain treatment
* Previous allergic response to local anesthetics or 5-HT3 receptor antagonists
* Patients who received analgesics or sedatives 24 h before scheduled surgery

Primary outcomes:
measure: change in postoperative pain between the two groups using visual analogue score (VAS)
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: The National Hepatology and Tropical Research medicine institute
Study officials:
References:
Clinical trial NCT03353285: Effect of Follicle Flushing on Oocyte Fertilization Rate
Official title: Effect of Follicle Flushing on Oocyte Fertilization Rate
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Infertility
Lead sponsor: Eugonia
Sponsor class: OTHER
First posted: 2017-11-27
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women undergoing IVF treatment

Brief summary: The purpose of this study is to investigate the impact of follicular flushing on fertilization rate in women undergoing IVF treatment

Detailed description: This will be a prospective observational study on the effect of follicular flushing on fertilization rate in women undergoing IVF treatment.

Oocytes from each woman will be allocated to one of three groups, depending on the aspirate or flush they are recovered from:

Group I= egg retrieved in the follicular fluid of the first aspirate (no flushing) Group II= egg retrieved in the 1st-2nd flush Group III= egg retrieved in the 3rd-5th flush

development and utilization. Pregnancy rates will be reported as a surrogate outcome.

Eligibility criteria: Inclusion Criteria:

* Up to 40 years old
* Both ovaries present
* Triggering final oocyte maturation using hCG or GnRH agonist

Exclusion Criteria:

* Egg donation
* PGD cases

Primary outcomes:
measure: Fertilization rate
timeFrame: Day 1 post oocyte retrieval
Secondary outcomes:
measure: Maturation rate
timeFrame: Day of oocyte retrieval
measure: Good quality embryos
timeFrame: Day 2 post oocyte retrieval
measure: Blastocyst formation rate
timeFrame: Day 5 post oocyte retrieval
Other outcomes:
Locations:
city: Athens
country: Greece
facility: Eugonia
Study officials:
affiliation: Eugonia
name: Tryfon G Lainas, Phd
role: STUDY_DIRECTOR
References:
citation: von Horn K, Depenbusch M, Schultze-Mosgau A, Griesinger G. Randomized, open trial comparing a modified double-lumen needle follicular flushing system with a single-lumen aspiration needle in IVF patients with poor ovarian response. Hum Reprod. 2017 Apr 1;32(4):832-835. doi: 10.1093/humrep/dex019.
citation: Franasiak JM. Follicular flushing: time to look elsewhere to improve in vitro fertilisation outcomes? BJOG. 2017 Jul;124(8):1197. doi: 10.1111/1471-0528.14628. No abstract available.
citation: Roque M, Sampaio M, Geber S. Follicular flushing during oocyte retrieval: a systematic review and meta-analysis. J Assist Reprod Genet. 2012 Nov;29(11):1249-54. doi: 10.1007/s10815-012-9869-9. Epub 2012 Oct 13.
Clinical trial NCT01530685: Gycabiane and Glycemic Control of Prediabetic Subjects
Official title: Effect of Glycabiane, a Dietary Supplement, on Glycemic Control of Prediabetic Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hyperglycemia
Keywords: cinnamon
chromium
prediabete
overweight
Lead sponsor: Larena SAS
Sponsor class: INDUSTRY
First posted: 2012-02-10
Enrollment: 83
Sex: ALL
Minimum age (years): 25
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to examine the effects of supplementation Glycabiane, a dietary supplement, on glycemic control of overweight prediabetic subjects.

Detailed description: Cinnamon's effects on blood glucose have been the subject of many clinical and animal studies; however, the issue of cinnamon intake's effect on fasting blood glucose (FBG) in people with prediabetes still remains unclear.

The main purpose of this study is to examine the effects of supplementation with Glycabiane, a dietary supplement rich in cinnamon extract, on fast blood glucose of overweight prediabetic subjects in a randomized, placebo-controlled, clinical trial.

Eligibility criteria: Inclusion Criteria:

* Male or female from 25 to 65 years old
* 1.0g/L ≤ fast blood glucose \< 1.26g/L
* overweight (IMC \> 25)

Exclusion Criteria:

* thyroid disease
* hypogonadism
* History of musculoskeletal, autoimmune or neurological disease
* Treatment against thyroid disease, hypoglycemia, hypertension, or anti-coagulant
* Pregnant or lactating women

Primary outcomes:
measure: Fast Blood Glucose
timeFrame: 4 months
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: CHU Pitié Salpetriere
Study officials:
affiliation: INSERM U872
name: Karine Clément, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Liu Y, Cotillard A, Vatier C, Bastard JP, Fellahi S, Stevant M, Allatif O, Langlois C, Bieuvelet S, Brochot A, Guilbot A, Clement K, Rizkalla SW. A Dietary Supplement Containing Cinnamon, Chromium and Carnosine Decreases Fasting Plasma Glucose and Increases Lean Mass in Overweight or Obese Pre-Diabetic Subjects: A Randomized, Placebo-Controlled Trial. PLoS One. 2015 Sep 25;10(9):e0138646. doi: 10.1371/journal.pone.0138646. eCollection 2015.
Clinical trial NCT00671385: Survey of Optical Values of the Breast Using Radiation-Free Pressure-Free Optical Scanning
Official title: Early Screening of Breast Cancer Using Radiation-Free Pressure-Free Optical Scanning
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Breast Lesions
Breast Cyst
Early-Stage Breast Cancer
Benign Growth, Breast
Keywords: screening
compositional analysis
metabolism
breast
breast cyst
breast infection
breast inflammation
lipoma
benign growth
Women without a diagnosis for a region of interest in the breast
Lead sponsor: Spectros Corporation
Sponsor class: INDUSTRY
Collaborators: name: Stanford University
name: University of California
name: Palo Alto Medical Foundation
First posted: 2008-05-05
Enrollment: 2000
Sex: FEMALE
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women 18-50 with who EITHER (a) have a region of interest but without a diagnosis, or (b) are healthy volunteers without breast cancer.

Brief summary: The purposes of this study is to establish normal optical values of breast tissue in the general population. This will allow for establishing normals for breast composition, and is expected to be useful in the classification of breast lesions into groups such as cysts, benign growths, inflammatory lesions, and possibly early breast cancer.


Eligibility criteria: Inclusion Criteria:

* You must be female
* You must be 21 to 50 years old
* You must not have or have had breast cancer.
* You must not have or have had breast implants or breast surgery
* You must not have had a breast biopsy or injury, or a breast infection, in 90 days.

Exclusion Criteria:

* Any one or more of the above conditions not met
* Lack of informed consent

Primary outcomes:
measure: Optical normals for the breast for a variety of conditions
timeFrame: 3 years
Secondary outcomes:
measure: Diagnostic compositional standards for (a) diagnosis of a condition such as cyst, benign growth, inflammation, and/or (b) referral for additional evaluation of a region of interest.
timeFrame: 1 year
Other outcomes:
Locations:
city: Portola Valley
country: United States
facility: Spectros Corporation
state: California
Study officials:
affiliation: Spectros Corporation
name: David A Benaron, MD
role: STUDY_DIRECTOR
References: